X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7806) 7806
Magazine Article (10) 10
Conference Proceeding (5) 5
Dissertation (2) 2
Book Chapter (1) 1
Book Review (1) 1
Newsletter (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5369) 5369
male (4410) 4410
female (3394) 3394
animals (3366) 3366
pyrroles - administration & dosage (2866) 2866
pyrroles - therapeutic use (2426) 2426
middle aged (2327) 2327
pyrroles - pharmacology (2326) 2326
atorvastatin calcium (2067) 2067
aged (1723) 1723
adult (1536) 1536
mice (1461) 1461
heptanoic acids - administration & dosage (1356) 1356
oncology (1356) 1356
pharmacology & pharmacy (1354) 1354
rats (1344) 1344
treatment outcome (1315) 1315
atorvastatin (1191) 1191
pyrroles - adverse effects (1127) 1127
heptanoic acids - therapeutic use (1024) 1024
dose-response relationship, drug (1021) 1021
sunitinib (956) 956
cancer (916) 916
indoles - administration & dosage (901) 901
indoles - therapeutic use (895) 895
statins (828) 828
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (752) 752
analysis (682) 682
expression (682) 682
care and treatment (675) 675
heptanoic acids - pharmacology (674) 674
carcinoma, renal cell - drug therapy (655) 655
cardiac & cardiovascular systems (634) 634
antineoplastic agents - therapeutic use (621) 621
research (621) 621
kidney neoplasms - drug therapy (612) 612
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (598) 598
time factors (573) 573
cholesterol (565) 565
drug therapy (559) 559
indoles - adverse effects (556) 556
disease models, animal (552) 552
pyrroles - pharmacokinetics (547) 547
therapy (535) 535
indoles - pharmacology (503) 503
drug administration schedule (502) 502
inflammation (491) 491
cell line, tumor (489) 489
administration, oral (484) 484
drug therapy, combination (483) 483
anticholesteremic agents - administration & dosage (479) 479
double-blind method (479) 479
aged, 80 and over (477) 477
simvastatin (476) 476
rats, sprague-dawley (475) 475
cholesterol, ldl - blood (456) 456
antineoplastic agents - administration & dosage (449) 449
neurosciences (447) 447
pyrimidines - therapeutic use (447) 447
efficacy (441) 441
abridged index medicus (435) 435
pyrimidines - administration & dosage (435) 435
risk factors (434) 434
medicine & public health (432) 432
tyrosine kinase inhibitor (418) 418
immunology (412) 412
pyrimidines - pharmacology (406) 406
mice, inbred c57bl (398) 398
kidney neoplasms - pathology (394) 394
anticholesteremic agents - therapeutic use (393) 393
endothelial growth-factor (390) 390
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (385) 385
niacinamide - analogs & derivatives (380) 380
angiogenesis (379) 379
indoleamine-pyrrole 2,3,-dioxygenase - metabolism (379) 379
health aspects (374) 374
rats, wistar (372) 372
pyrroles - chemistry (371) 371
metastasis (368) 368
safety (367) 367
inhibition (364) 364
tumors (358) 358
biochemistry & molecular biology (355) 355
heptanoic acids - adverse effects (354) 354
antineoplastic agents - adverse effects (351) 351
apoptosis (348) 348
rodents (343) 343
retrospective studies (340) 340
antineoplastic agents (338) 338
atherosclerosis (329) 329
disease (327) 327
hypercholesterolemia - drug therapy (327) 327
prospective studies (327) 327
medicine, general & internal (324) 324
chemotherapy (320) 320
antimitotic agents (319) 319
follow-up studies (319) 319
interferon-alpha (316) 316
antineoplastic combined chemotherapy protocols - therapeutic use (315) 315
protein kinase inhibitors - therapeutic use (315) 315
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7563) 7563
Japanese (96) 96
German (80) 80
Russian (39) 39
French (34) 34
Chinese (28) 28
Italian (25) 25
Spanish (20) 20
Hungarian (8) 8
Polish (7) 7
Czech (5) 5
Swedish (5) 5
Ukrainian (5) 5
Danish (2) 2
Dutch (2) 2
Korean (2) 2
Lithuanian (2) 2
Norwegian (2) 2
Croatian (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA : the journal of the American Medical Association, ISSN 0098-7484, 05/2014, Volume 311, Issue 18, pp. 1870 - 1882
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
...). However, the potential for drug interactions with co‐administration of GSK2248761 and other antiretroviral medications or supportive medications is not known... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 2012, Volume 30, Issue 32, pp. 4017 - 4025
Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its... 
ANTI-CD20 MONOCLONAL-ANTIBODY | ONCOLOGY | FC-GAMMA-RIIIA | PROGRESSION-FREE SURVIVAL | MULTICENTER PHASE-II | SQUAMOUS-CELL CARCINOMA | TYROSINE KINASE INHIBITOR | ENDOTHELIAL GROWTH-FACTOR | SUNITINIB MALATE SU11248 | CHRONIC MYELOID-LEUKEMIA | IMATINIB PLASMA-LEVELS | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Thiazoles - blood | Injections, Intravenous | Area Under Curve | Pyrimidines - blood | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Half-Life | Thiazoles - administration & dosage | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Drug Monitoring - methods | Indoles - administration & dosage | Antibodies, Monoclonal - blood | Antibodies, Monoclonal, Humanized | Neoplasms - blood | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Cetuximab | Piperazines - blood | Everolimus | Molecular Targeted Therapy - methods | Dasatinib | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Indoles - blood | Rituximab | Pyrroles - blood | Sirolimus - blood | Evidence-Based Medicine | Imatinib Mesylate | Neoplasms - drug therapy | Sirolimus - administration & dosage | Antibodies, Monoclonal, Murine-Derived - blood | Pyridines - blood | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - blood | Benzamides
Journal Article
Gut, ISSN 0017-5749, 09/2016, Volume 65, Issue 9, pp. 1439 - 1446
ObjectiveThe objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a... 
antibiotic therapy | clinical trials | Helicobacter pylori infection | helicobacter pylori - treatment | CLARITHROMYCIN | LANSOPRAZOLE | MULTICENTER | MANAGEMENT | CLINICAL-TRIAL | PHARMACOKINETICS | JAPAN | INFECTION | MONOFUMARATE TAK-438 | GASTROENTEROLOGY & HEPATOLOGY | AMOXICILLIN | Humans | Middle Aged | Helicobacter Infections - complications | Helicobacter pylori - drug effects | Male | Drug Monitoring - methods | Proton Pump Inhibitors - administration & dosage | Pyrroles - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Peptic Ulcer - diagnosis | Pyrroles - adverse effects | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Helicobacter Infections - diagnosis | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Double-Blind Method | Drug Administration Schedule | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Treatment Outcome | Drug Therapy, Combination - methods | Lansoprazole - adverse effects | Sulfonamides - adverse effects | Amoxicillin - adverse effects | Helicobacter pylori - isolation & purification | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Breath Tests - methods | Peptic Ulcer - etiology | Sulfonamides - administration & dosage | Usage | Safety and security measures | Research | Helicobacter pylori | Antacids | Helicobacter Pylori | HELICOBACTER PYLORI - TREATMENT | CLINICAL TRIALS | 1506 | ANTIBIOTIC THERAPY | HELICOBACTER PYLORI INFECTION
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 25, pp. 2377 - 2386
In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and... 
MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | ADALIMUMAB | RECOMMENDATIONS | COMBINATION THERAPY | JOINT DAMAGE | DISEASE | PLUS METHOTREXATE | DOUBLE-BLIND | ETANERCEPT | CP-690,550 | Herpes Zoster - etiology | Antirheumatic Agents - administration & dosage | Arthritis, Rheumatoid - blood | Cholesterol - blood | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Arthritis, Rheumatoid - complications | Dose-Response Relationship, Drug | Janus Kinase 3 - antagonists & inhibitors | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Piperidines - administration & dosage | Double-Blind Method | Administration, Oral | Pyrimidines - administration & dosage | Methotrexate - adverse effects | Protein Kinase Inhibitors - administration & dosage | Piperidines - adverse effects | Pyrimidines - adverse effects | Creatinine - blood | Methotrexate - administration & dosage | Care and treatment | Dosage and administration | Tofacitinib | Comparative analysis | Methotrexate | Rheumatoid arthritis | Creatinine | Herpes zoster | C-reactive protein | Kinases | Joint diseases | Lymphoma | Sedimentation | Cholesterol | Pain | Rheumatism | Janus kinase | Erythrocyte sedimentation rate | Drug therapy | Pharmaceuticals | Cancer
Journal Article
by Fleischmann, Roy and Mysler, Eduardo and Hall, Stephen and Kivitz, Alan J and Moots, Robert J and Luo, Zhen and DeMasi, Ryan and Soma, Koshika and Zhang, Richard and Takiya, Liza and Tatulych, Svitlana and Mojcik, Christopher and Krishnaswami, Sriram and Menon, Sujatha and Smolen, Josef S and Adams, Luthando and Ally, Mahmood M and du Plooy, Maria C and Louw, Ingrid C and Nayiager, Savithree and Nel, Christoffel B and Nel, Debra and Reuter, Helmuth and Soloman, Ahmed S and Spargo, Catherine E and Rischmueller, Maureen and Sharma, Shunil D and Will, Robert K and Youssef, Peter P and Arroyo, Caroline and Baes, Rosario P and Dulos, Roger B and Hao, Llewellyn T and Lanzon, Allan E and Lichauco, Juan Javier T and Mangubat, Jill H and Ramiterre, Edgar B and Reyes, Bernadette Heizel M and Tan, Perry P and Choe, Jung-Yoon and Kang, Young Mo and Kwon, Seong Ryul and Lee, Sang-Heon and Lee, Shin-Seok and Yoo, Dae-Hyun and Lin, Hsiao-Yi and Luo, Shue-Fen and Tsai, Shih-Tzu and Tsai, Wen-Chan and Tseng, Jui-Cheng and Wei, Cheng-Chung C and Asavatanabodee, Paijit and Nantiruj, Kanokrat and Nilganuwong, Surasak and Uea-Areewongsa, Parichat and Majstorovic, Ljubinka Bozic and Bacic, Suada Mulic and Batalov, Anastas Z and Georgieva-Slavcheva, Gabriela and Mihailova, Mariyana and Nikolov, Nikolay G and Penev, Dimitar P and Spasov, Yuliy A and Stanimirova, Krasimira and Todorov, Stoyan and Toncheva, Antoaneta R and Yordanova, Nadezhda and Mosterova, Zdenka and Novosad, Libor and Prochazkova, Leona and Stehlikova, Helena and Stejfova, Zuzana and Kiseleva, Natalia and Pank, Lea and Savi, Triin and Alexandra, Balbir-Gurman and Amital, Howard and Mevorach, Dror and Rosner, Itzhak A and Mihailova, Anna and Stumbra-Stumberga, Evija and Basijokiene, Vida and Lietuvininkiene, Virginija and Unikiene, Dalia and Brzezicki, Jan and Dudek, Anna M and Glowacka-Kulesz, Maria B and Grabowicz-Wasko, Barbara and Hajduk-Kubacka, Sabina and Hilt, Joanna and Hrycaj, Pawel and Jeka, Slawomir and Kolasa, Renata and Krogulec, Marek and Mastalerz, Hanna and Olak-Popko, Anna and Owczarek, Elzbieta and Ruzga, Zofia and Walczak, Alina and Ancuta, Codrina I and ... and ORAL Strategy investigators and ORAL Strategy Investigators
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 390, Issue 10093, pp. 457 - 468
Summary Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | NECROSIS-FACTOR | PLACEBO | JANUS KINASE INHIBITOR | INADEQUATE RESPONSE | LONG-TERM SAFETY | PLUS METHOTREXATE | AMERICAN-COLLEGE | OPEN-LABEL | COMBINATION | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Methotrexate - therapeutic use | Adalimumab - adverse effects | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Drug Therapy, Combination | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Piperidines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Treatment Outcome | Methotrexate - adverse effects | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Methotrexate - administration & dosage | Rheumatoid factor | Care and treatment | Analysis | Clinical trials | Arthritis | Pharmaceutical industry | Methotrexate | Rheumatology | Patients | Evidence-based medicine | Studies | Rheumatoid arthritis | Monoclonal antibodies | Rheumatism | TNF inhibitors | Janus kinase | Tumor necrosis factor-TNF | Safety | Drug therapy | Drug dosages
Journal Article
Analytical and bioanalytical chemistry, ISSN 1618-2650, 2018, Volume 410, Issue 11, pp. 2815 - 2828
... (TEC) determinations of four different molecules in cross sections of human skin explants after topical administration... 
Biochemistry, general | Skin penetration | Food Science | Quantification | Drug distribution | Mass spectrometry imaging | Human skin | Laboratory Medicine | MALDI-MSI | Chemistry | Analytical Chemistry | Monitoring/Environmental Analysis | Characterization and Evaluation of Materials | CHEMISTRY, ANALYTICAL | HUMAN STRATUM-CORNEUM | BIOCHEMICAL RESEARCH METHODS | PENETRATION | MOLECULAR-SIZE | MICROSCOPY | MASS-SPECTROMETRY | TISSUE-SECTIONS | ATOPIC-DERMATITIS | PERCUTANEOUS-ABSORPTION | PSORIASIS | Pyrroles - pharmacokinetics | Benzamides - pharmacokinetics | Skin - metabolism | Humans | Aminopyridines - pharmacokinetics | Pyridines - pharmacokinetics | Drug Discovery - methods | Benzamides - administration & dosage | Cyclopropanes - administration & dosage | Phosphodiesterase 4 Inhibitors - administration & dosage | Pyrroles - administration & dosage | Piperidines - pharmacokinetics | Pyrazoles - pharmacokinetics | Cyclopropanes - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Aminopyridines - administration & dosage | Piperidines - administration & dosage | Pyridines - administration & dosage | Acetamides - pharmacokinetics | Phosphodiesterase 4 Inhibitors - pharmacokinetics | Pyrimidines - administration & dosage | Skin Absorption | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Pyrimidines - pharmacokinetics | Administration, Topical | Acetamides - administration & dosage | Pharmaceutical research | Topical medication | Pharmaceutical industry | Innovations | Testing | Formulations | Explants | Psoriasis | Medical treatment | Spatial discrimination | Imaging techniques | Ions | Mass spectroscopy | Desorption | Drug development | Tissues | Dermatitis | Ionization | Lasers | Atopic dermatitis | Imaging | Skin diseases | Skin | Mass spectrometry | Spatial resolution | Physicochemical properties
Journal Article